Texas Pharmaceutical & Therapeutics Committee – July Meeting outcome
7/
29
Texas Pharmaceutical & Therapeutics Committee – July Meeting outcome
On July 24th, the Texas Pharmaceutical and Therapeutics (P&T) Committee, a part of the Texas Health and Human Services Commission, convened to review a number of different medications and medication classes for entry onto their Preferred Drug List (PDL) of the Texas Medicaid Formulary. A medication to alleviate symptoms of opioid-induced constipation (OIC) was one of the drugs under review.
Mickey Goodwin, an advocate from Lubbock, Texas, provided the only patient testimony at the meeting, urging the Committee to improve access to OIC medications. In representing people across Texas with OIC, Mickey played a key role in the Committee’s decision-making process.
We are grateful to Mickey for her willingness and strength to step up and share her story. While the P&T Committee did not vote to place the particular OIC medication on its PDL, the Committee did classify the medication as a non-preferred drug (NPD), adding it to a list of OIC drugs that physicians and their patients can access. Though obtainability of the medication will be somewhat more difficult, we are hopeful.
In October, the P&T Committee will be reviewing the entire gastrointestinal motility drug class: the fight continues! We will have another opportunity to have gastrointestinal motility drugs added to the state’s PDL at that time.
For more information on OIC, this initiative, and how you can join the fight, click here: